BFRI Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States...

Stats
Today's Volume	66 230.00
Average Volume	780 203
Market Cap	8.60M
EPS	$0 ( 2024-03-18 )
Next earnings date	( $-1.630 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.130
ATR14	$0.0210 (1.26%)

Insider Trading

Date	Person	Action	Amount	type
2023-07-03	Lanckriet Heikki	Buy	0
2023-05-18	Monaco Erica L.	Buy	76 336	Common Stock
2023-05-18	Monaco Erica L.	Sell	76 336	Restricted Stock Units
2023-05-18	Luebbert Hermann	Buy	95 420	Common Stock
2023-05-18	Luebbert Hermann	Sell	95 420	Restricted Stock Units

INSIDER POWER
27.51
Last 24 transactions
Buy: 1 247 993 \| Sell: 171 756

Volume Correlation

Long: -0.28 (neutral)

Short: -0.27 (neutral)

Signal:(38.889) Neutral

Biofrontera Inc. Correlation

10 Most Positive Correlations
NAKD	0.956
TRIT	0.953
AVIR	0.946
RMRM	0.933
ALXO	0.932
LSXMK	0.932
LSXMA	0.932
IMV	0.931
STRO	0.928
ATSG	0.927

10 Most Negative Correlations
TGTX	-0.945
SLMBP	-0.942
PAE	-0.941
ATRS	-0.941
MEOH	-0.94
DHCAU	-0.938
IDCC	-0.936
PRAA	-0.936
PDFS	-0.933
ANSS	-0.933

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Biofrontera Inc. Correlation - Currency/Commodity

0.31
( neutral )

0.45
( neutral )

0.00
( neutral )

0.38
( neutral )

-0.47
( neutral )

-0.59
( weak negative )

Biofrontera Inc. Financials

Annual	2023
Revenue:	$34.07M
Gross Profit:	$15.56M (45.68 %)
EPS:	$-13.02

Q4	2023
Revenue:	$10.60M
Gross Profit:	$4.93M (46.56 %)
EPS:	$1.650

Q3	2023
Revenue:	$8.88M
Gross Profit:	$4.38M (49.37 %)
EPS:	$-4.64

Q2	2023
Revenue:	$5.85M
Gross Profit:	$2.96M (50.62 %)
EPS:	$-7.23

Financial Reports:

No articles found.

Biofrontera Inc.

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.